One of the greatest challenges in healthcare is the lack of a safe, early stage cancer screening test. Patients with early cancer often have no symptoms and so they are unaware of the threat and that a cancer may be spreading.
We have the 1st point of care screening test covered by two pending US patents. The screening technology has been tested on thousands of patients in numerous clinical trials conducted in the US, Canada, Asia and Europe.
LUNG cancer - There is no standard screening test. Chest CTs are seldom used, as they are costly and emit a lot of radiation -15 x that of a chest Xray
BREAST cancer- Mammograms are not an ideal screening test, as they emit radiation and most importantly, may miss up to 40% of early stage cancers.
PROSTATE cancer- The current PSA test has accuracy issues differentiating between an enlarged prostate (BPH) from a cancerous prostate.
COLON cancer- Stool testing for blood has a high false positive rate & more importantly may miss early stage tumors that are not bleeding. The newer Blood & DNA stool test is costly, more than 8 times our price of $75.
UTERINE cancer- There is no screening test available for this type of cancer
One in 4 people will be diagnosed with lung, colon, breast or prostate cancer, and these 4 cancers account for almost half of all cancer deaths. Lung cancer alone is responsible for more than 140,000 deaths each year in the US, or approximately 1/4 of all cancer mortality.
The aim is to make our tests an essential component of annual physical exams, which we expect will substantially increase awareness and demand.
Half of the US population of 330 million are 35 years of age or older. Our market is thus 165 million people, as age is the main risk factor for these 4 cancers.
The cost of the test kits are expected to be less than 10% of our anticipated selling price of less than $95 for a single test kit and $195 for a 3 piece test kit.
Sales revenue could be over $300 million for each 1% tested (1.65 million people x $195 3 pc kit for men and a 4 pc kit for women)
This makes the US market opportunity over $30 billion annually. Plus expansion into Canada, Europe, Asia, etc. should further enhance our revenue.
We offer a unique investment opportunity. Investors will receive a royalty from the sale of test kits, which may allow them to recoup their entire investment back, and at the same time Investors will receive shares in Early Detection Inc.
For more investment information please contact
Dr. Kim Vanderlinden at:
Early detection Inc. can start selling the tests while abiding by FDA rules, because the tests are very safe, and thus have very low risk. In fact, there is more than one pathway that we intend to use, as we go to market. Our Executive Summary describes our commercialization strategy.
Most of our clinical trials were conducted in the 1990s and 2000s, however this does not make them obsolete in any way, as humans have not changed. What could make these tests obsolete, is if another more accurate test was invented and clinically validated and this simply has not happened.
In the news the last few years is cancer screening research that looks for DNA and RNA in the blood. Similar to our altered sugar research, RNA and DNA cancer screening research has also been taking place for decades. Two of the main screening technologies/companies are called GRAIL and Thrive. The challenge is that when cancers are small, as is common in early-stage cancers, it results in very small amounts of RNA or DNA in the blood, which then makes early-stage cancers harder to detect.
In the recent GRAIL study the technology detected 39% of stage 1 cancers. The company was offered $8 Billion in the fall of 2020.
Recent 2020 study results of Thrive’s blood test’s showed a sensitivity of 27.1% across all cancers and 31.1% for the seven cancers with no screening options. In 2020 this company sold for $2 billion.
A key advantage of GRAIL and Thrive's testing is that they attempt to detect several kinds of cancer that our testing does not. Whereas, our testing will focus on the "Big 4", or lung, colon, breast and prostate. There is also a good potential for a uterine cancer screen, which is the 9th most common cancer in the US with more than 50,000 cases diagnosed annually resulting in more than 12,000 deaths.
Most importantly, the clinical trial data to date, indicates that our technology detects a much higher percentage of early stage cancers.
Here is a link to a review article published in April 2021.
From time to time Early Detection, Inc. (the “Company”) may provide information to others about the Company. Such information should not be considered as an offer or invitation to subscribe for or purchase any securities in the Company or as an inducement to make an offer or invitation with respect to those securities. No agreement to subscribe for securities in the Company will be entered into on the basis of such information.
This additional information about the Company is not intended to be a prospectus or other offering document under U.S. law or under any other law. It has been prepared for information purposes only. It is not investment advice. Prospective investors should obtain their own independent advice from qualified financial advisors having regard to their objectives, financial situation, and needs.
Such information may contain forward-looking statements. Any information which is not historical information should be considered forward-looking statements. Such information is not a guarantee of future performance and involves unknown risks and uncertainties. Actual results and developments will almost certainly differ materially from those expressed or implied in such forward-looking statements. There are a number of risks, both specific to the Company, and of a general nature which may affect the future operating and financial performance of the Company, and the value of an investment in the Company, including and not limited to economic conditions, stock market fluctuations, success of clinical trials, regulatory risks, operational risks, and reliance on key personnel.
The statements on this website have not been evaluated by the Food and Drug Administration. The products are screening tests only and are not intended to diagnose, treat, cure or to prevent any disease.